141
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment

, , , , , , , , & show all
Pages 1199-1211 | Published online: 22 Jul 2019

References

  • Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.28264816
  • Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis. 2003;62:611–616. doi:10.1136/ard.62.7.61112810421
  • Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903–911. doi:10.1016/S0140-6736(01)06075-511567728
  • Waimann C, Marengo M, Achaval de S, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis. Consequences of low adherence. Arthritis Rheum. 2013;65(6):1421–1429. doi:10.1002/art.3791723728826
  • van den Bemt BJF, van den Hoogen FH, Benraad B, Hekster Y, van Riel PL, van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009;36(10). doi:10.3899/jrheum.080430
  • Pasma A, den Boer E, van Spijker A, et al. Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients. Rheumatology(Oxford). 2016;55(10):1812–1819. doi:10.1093/rheumatology/kew24727354686
  • Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335–344.20016797
  • Stacey D, Légaré F, Col N, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;(1):CD001431.
  • Mühlbacher A, Johnson F. Choice experiments to quantify preferences for health and healthcare: state of the practice. Appl Heal Econ Heal Policy. 2016;14(3):253–266. doi:10.1007/s40258-016-0232-7
  • Nolla JM, Rodríguez M, Martin-Mola E, et al. Patients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Prefer Adherence. 2016;10:1101–1113. doi:10.2147/PPA.S10631127382258
  • Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework.PLoS One. 2013;8(12):e80633. doi:10.1371/journal.pone.008063324312488
  • Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abus Treat. 2016;66:48–53. doi:10.1016/j.jsat.2016.02.009
  • Chapman S, Dale P, Svedsater H, et al. Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication. NPJ Prim Care Respir Med. 2017;27(61). doi:10.1038/s41533-017-0061-7.
  • Alten R, Krüger K, Rellecke J, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217–2228. doi:10.2147/PPA.S11777427843301
  • von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349. doi:10.1016/j.jclinepi.2007.11.00818313558
  • Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Heal. 2011;4:403–413. doi:10.1016/j.jval.2010.11.013
  • Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Heal. 2013;16(1):3–13. doi:10.1016/j.jval.2012.08.2223
  • Mathijssen EG, van Heuckelum M, van Dijk L, et al. A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels. Patient Prefer Adherence. 2018;12:1537–1555. doi:10.2147/PPA.S17072130197505
  • Zwikker HE, van Dulmen S, van den Bemt BJ, van den Ende C. Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. Patient Prefer Adherence. 2014;8:1635–1645. doi:10.2147/PPA.S6684925525340
  • Menckeberg TT, Bouvy ML, Bracke M, et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res. 2008;64(1):47–54. doi:10.1016/j.jpsychores.2007.07.01618157999
  • Orme B. Sample size issues for conjoint analysis In: Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research. Madison: Research Publishers LLC; 2010:57–66.
  • Kongsted A, Nielsen A. Latent class analysis in health research. J Physiother. 2017;63(1):55–58. doi:10.1016/j.jphys.2016.05.01827914733
  • Hauber AB, González JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Heal. 2016;4:300–315. doi:10.1016/j.jval.2016.04.004
  • Fraenkel L, Nowell WB, Michel G, Wiedmeyer C. Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. Ann Rheum Dis. 2018;77(5):678–683. doi:10.1136/annrheumdis-2017-21240729247126
  • Husni ME, Betts KA, Griffith J, Song Y, Ganguli A. Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. Rheumatol Int. 2017;37(9):1423–1434. doi:10.1007/s00296-017-3760-z28623526
  • Poulos C, Hauber AB, González JM, Turpcu A. Patients’ willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res. 2014;66(7):1008–1015. doi:10.1002/acr.22265
  • Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology(Oxford). 2010;49(2):289–294. doi:10.1093/rheumatology/kep35419920093
  • Louder AM, Singh A, Saverno K, et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Heal Drug Benefits. 2016;9(2):84–93.
  • Huynh TK, Østergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93–99. doi:10.2147/PPA.S5515624470758
  • Hazlewood G, Bombardier C, Tomlinson G, et al. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. Rheumatology(Oxford). 2016;55(11):1959–1968. doi:10.1093/rheumatology/kew28027477807
  • Augustovski F, Beratarrechea A, Irazola V, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Heal. 2013;16(2):385–393. doi:10.1016/j.jval.2012.11.007
  • Horne R, Parham R, Driscoll R, Robinson A. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(6):837–844. doi:10.1002/ibd.2084619107771
  • Salampessy BH, Veldwijk J, Schuit AJ, de Wit GA, Lambooij MS. The predictive value of discrete choice experiments in public health: an exploratory application. Patient. 2015;8(6):521–529. doi:10.1007/s40271-015-0115-225618790